Recent Updates — RDGL
On October 30, 2026, Vivos Inc. completed the sale of 12,500,000 shares of common stock in a Regulation A+ best-efforts offering, generating gross proceeds of $1,000,000 for general working capital. The company also issued warrants to purchase 25,000,000 additional shares to accredited investors for $25,000, exercisable at $0.075 per share and expiring December 31, 2030. Additionally, Vivos exchanged 8,000,000 warrants for 8,000,000 shares of common stock. The company will hold its annual meeting on December 9, 2026. Vivos Inc. operates in the medical device industry, focusing on minimally invasive treatments for sleep apnea and bruxism.
On October 7, 2026, Vivos Inc. entered into a Stock Purchase and Exchange Agreement with Carl Cadwell, a member of its Board of Directors. Pursuant to the agreement, Cadwell purchased 250,000 shares of Series D Convertible Preferred Stock for $250,000 and exchanged his existing 385,302 shares of Series C Convertible Preferred Stock for an equal number of Series D shares. The transaction was consummated on the same date, resulting in 635,302 total Series D shares outstanding with a conversion price of $0.08 per share and zero Series C shares remaining. On October 8, 2026, the company filed a Certificate of Elimination to formally cancel the Series C Convertible Preferred Stock class. Vivos Inc. operates in the biotechnology sector, focusing on cancer treatment technologies.
On September 28, 2026, Vivos Inc filed a Certificate of Designations creating 1.0 million shares of Series D Convertible Preferred Stock. Each share carries a $1.00 stated value and liquidation preference, ranking senior to common stock. The preferred stock is convertible into common shares at a rate derived from the $1.00 stated value divided by $0.08. Holders receive voting rights equivalent to fifty votes per common share issuable upon conversion. A beneficial ownership limitation restricts conversion if it would result in owning more than 4.99% of outstanding common stock, unless increased to 9.99% with notice. Vivos Inc operates in the biotechnology sector, focusing on cancer treatment technologies.